Cisplatin is a platinum-based chemotherapeutic agent that induces peripheral neuropathy in 30% of patients. Peripheral neuropathy is the dose limiting side effect, which has no preventative therapy. We have previously shown that cisplatin induces apoptosis in dorsal root ganglion (DRG) sensory neurons by covalently binding to nuclear DNA (nDNA), resulting in DNA damage, subsequent p53 activation and Bax-mediated apoptosis via the mitochondria. We now demonstrate that cisplatin also directly binds to mitochondrial DNA (mtDNA) with the same binding affinity as nDNA. Cisplatin binds 1 platinum molecule per 2166 mtDNA base pairs and 1 platinum molecule per 3800 nDNA base pairs. Furthermore, cisplatin treatment inhibits mtDNA replication as detected by 5-bromo-2′-deoxy-uridine (BrdU) incorporation and inhibits transcription of mitochondrial genes. The relative reduction in mtDNA transcription is directly related to the distance the gene is located from the transcription initiation point, which implies that randomly formed platinum adducts block transcription. Cisplatin treated DRG neurons exhibit mitochondrial vacuolization and degradation in vitro and in vivo. Taken together, this data suggests that direct mtDNA damage may provide a novel, distinct mechanism for cisplatin-induced neurotoxicity separate from the established nDNA damage pathway.
Introduction
Platinum-based chemotherapy (e.g. cisplatin, carboplatin and oxaliplatin) is used to treat various types of cancers including prostate, testicular, ovarian, and colon cancers. The dose limiting side effect of these drugs is peripheral neuropathy, which reduces the quality of life for many long-term cancer survivors. Cisplatin-induced peripheral neuropathy occurs in about 30% of patients with 20% being forced to discontinue treatment (Cavaletti, 2008; Thompson et al., 1984; Windebank and Grisold, 2008) . Patients with cisplatin-induced peripheral neuropathy experience sensory loss, often accompanied by pain, starting in the distal extremities. Although cisplatin treatment is customarily discontinued once neuropathic symptoms begin, worsening of the symptoms may continue for weeks or months. This phenomenon, commonly known as "coasting," is observed exclusively in platinum-based chemotherapy and suggests that there is ongoing neuronal damage after discontinuing cisplatin (Grunberg et al., 1989) .
Cisplatin-induced nuclear DNA (nDNA) damage in dorsal root ganglion (DRG) neurons has been thoroughly investigated. Cisplatin covalently binds to nuclear DNA (nDNA) inducing DNA damage and apoptosis (Eastman, 1987; Woynarowski et al., 1998) . Cisplatin-induced DNA damage up-regulates p53 and induces cell cycle changes in DRG neurons (Fischer et al., 2001a) . Cell cycle changes include up-regulation of cyclin D1, activation of CDK4/6 complexes and phosphorylation of Rb. All of these events lead to Bax translocation to the mitochondria, cytochrome-c release, caspase activation and apoptosis (Gill and Windebank, 1998; McDonald and Windebank, 2002) . In culture, DRG neuron survival is dependent on maintenance levels of nerve growth factor (NGF). Increasing the concentration of NGF ten fold prevents both Bax translocation to the mitochondria and cell cycle changes observed in cisplatin treated DRG neurons (McDonald and Windebank, 2002) .
Previous studies have shown that cisplatin binds to mitochondrial DNA in liver and B50 cells (Bottone et al., 2008) . Mitochondrial DNA is a circular~16,300 bp piece of DNA that encodes for 13 proteins essential for the various subunits of the electron transport chain including complex I (NADH dehydrogenase 1, 2, 3, 4, 4L, 5 and 6), complex III (cytochrome b), complex IV (cytochrome c oxidase 1, 2 and 3) and ATP synthase 6 and 8. Mitochondrial DNA also encodes for 22 tRNA and 2 rRNA that are important for synthesis of these proteins. Both replication and transcription are unidirectional from one start point (Asin-Cayuela and Gustafsson, 2007; Clayton, 1991) .
The effects of cisplatin on DRG mitochondrial DNA (mtDNA) have not been investigated. Given that mtDNA differs from nDNA in several ways, it follows that cisplatin effects on mtDNA likely differ as well, and that these effects could contribute to cisplatin-induced neurotoxicity. Previous studies in neuronal systems have addressed total platinum-DNA adduct formation without making a distinction between nDNA and mtDNA. It has been shown that DRG neurons accumulate high levels of cisplatin-DNA adducts in vitro and in vivo 
